Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Nov;69(5):636–641. doi: 10.1136/jnnp.69.5.636

Effects of topiramate on cognitive function

P Thompson 1, S Baxendale 1, J Duncan 1, J Sander 1
PMCID: PMC1763392  PMID: 11032616

Abstract

OBJECTIVE—To explore the impact of topiramate on tests of intellect and other cognitive processes.
METHODS—This was a retrospective study. The neuropsychological test scores of 18 patients obtained before and after the introduction of treatment with topiramate (median dose 300 mg) were compared with changes in test performance of 18 patients who had undergone repeat neuropsychological assessments at the same time intervals. Complaints of cognitive decline precipitated referral for reassessment in five cases in the topiramate treated group. The groups were matched for age and intellectual level at the time of the first assessment. Patients were assessed using the WAIS-R, tests of verbal and non-verbal memory, language, and perceptual processing. A subgroup of patients underwent a brief reassessment after the withdrawal or substantial reduction of topiramate.
RESULTS—Repeat assessments in those taking topiramate were associated with a significant deterioration in many domains, which were not seen in the comparison group. The greatest changes were for verbal IQ, verbal fluency, and verbal learning (p<0.001). Improvements in verbal fluency (p<0.05), verbal learning (p<0.01), and digit span (p<0.001) were recorded in those patients who had topiramate withdrawn or reduced.
CONCLUSIONS—In our patient group topiramate had a negative impact on cognition which was consistent with subjective complaints of patients. Tests requiring verbal processing seemed especially sensitive to the drug. A decline in verbal intellect (VIQ), a measure which has been considered by some to be insensitive to antiepileptic drug effects, was particularly striking. Caution is warranted in the interpretation of the findings due to methodological limitations of the study design. Further investigation of mediating factors such as serum concentrations, comedication, and other potential risk factors, however, is needed to enable appropriate targeting of treatment with this effective antiepileptic agent.



Full Text

The Full Text of this article is available as a PDF (152.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andermann L. F., Savard G., Meencke H. J., McLachlan R., Moshé S., Andermann F. Psychosis after resection of ganglioglioma or DNET: evidence for an association. Epilepsia. 1999 Jan;40(1):83–87. doi: 10.1111/j.1528-1157.1999.tb01992.x. [DOI] [PubMed] [Google Scholar]
  2. Burton L. A., Harden C. Effect of topiramate on attention. Epilepsy Res. 1997 Apr;27(1):29–32. doi: 10.1016/s0920-1211(96)01015-7. [DOI] [PubMed] [Google Scholar]
  3. Coughlan A. K., Warrington E. K. Word-comprehension and word-retrieval in patients with localized cerebral lesions. Brain. 1978 Mar;101(1):163–185. doi: 10.1093/brain/101.1.163. [DOI] [PubMed] [Google Scholar]
  4. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure. 1998 Jun;7(3):207–211. doi: 10.1016/s1059-1311(98)80037-x. [DOI] [PubMed] [Google Scholar]
  5. Elterman R. D., Glauser T. A., Wyllie E., Reife R., Wu S. C., Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology. 1999 Apr 22;52(7):1338–1344. doi: 10.1212/wnl.52.7.1338. [DOI] [PubMed] [Google Scholar]
  6. Jokeit H., Ebner A. Long term effects of refractory temporal lobe epilepsy on cognitive abilities: a cross sectional study. J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):44–50. doi: 10.1136/jnnp.67.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jones M. W. Topiramate--safety and tolerability. Can J Neurol Sci. 1998 Aug;25(3):S13–S15. doi: 10.1017/s0317167100034855. [DOI] [PubMed] [Google Scholar]
  8. Kellett M. W., Smith D. F., Stockton P. A., Chadwick D. W. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):759–763. doi: 10.1136/jnnp.66.6.759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Martin R., Kuzniecky R., Ho S., Hetherington H., Pan J., Sinclair K., Gilliam F., Faught E. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999 Jan 15;52(2):321–327. doi: 10.1212/wnl.52.2.321. [DOI] [PubMed] [Google Scholar]
  10. Privitera M., Fincham R., Penry J., Reife R., Kramer L., Pledger G., Karim R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology. 1996 Jun;46(6):1678–1683. doi: 10.1212/wnl.46.6.1678. [DOI] [PubMed] [Google Scholar]
  11. Tassinari C. A., Michelucci R., Chauvel P., Chodkiewicz J., Shorvon S., Henriksen O., Dam M., Reife R., Pledger G., Karim R. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 1996 Aug;37(8):763–768. doi: 10.1111/j.1528-1157.1996.tb00649.x. [DOI] [PubMed] [Google Scholar]
  12. Vermeulen J., Aldenkamp A. P. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res. 1995 Oct;22(2):65–95. doi: 10.1016/0920-1211(95)00047-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES